149 related articles for article (PubMed ID: 19806507)
1. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes.
Tomkin GH
Curr Opin Mol Ther; 2009 Oct; 11(5):579-88. PubMed ID: 19806507
[TBL] [Abstract][Full Text] [Related]
2. Albiglutide: a review of its use in patients with type 2 diabetes mellitus.
Blair HA; Keating GM
Drugs; 2015 Apr; 75(6):651-63. PubMed ID: 25777969
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
4. Albiglutide: Is a better hope against diabetes mellitus?
Sharma AK; Thanikachalam PV; Rajput SK
Biomed Pharmacother; 2016 Feb; 77():120-8. PubMed ID: 26796275
[TBL] [Abstract][Full Text] [Related]
5. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
Davis PN; Ndefo UA; Oliver A; Payton E
Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
[TBL] [Abstract][Full Text] [Related]
6. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
[TBL] [Abstract][Full Text] [Related]
8. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes.
St Onge EL; Miller SA
Expert Opin Biol Ther; 2010 May; 10(5):801-6. PubMed ID: 20367248
[TBL] [Abstract][Full Text] [Related]
9. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
Scheen AJ
Rev Med Liege; 2015 Apr; 70(4):207-14. PubMed ID: 26054173
[TBL] [Abstract][Full Text] [Related]
10. Developments of glucagon like peptide-1 (GLP-1) and long-acting analogs in clinical and preclinical studies for treatment of type 2 diabetes.
Li Y; Tang L; Gong M
Curr Pharm Biotechnol; 2013; 14(9):835-41. PubMed ID: 24372261
[TBL] [Abstract][Full Text] [Related]
11. Peptide complex containing GLP-1 exhibited long-acting properties in the treatment of type 2 diabetes.
Zheng X; Li Y; Li X; Tang L; Xu W; Gong M
Diabetes Res Clin Pract; 2011 Sep; 93(3):410-20. PubMed ID: 21641071
[TBL] [Abstract][Full Text] [Related]
12. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Brønden A; Naver SV; Knop FK; Christensen M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1493-503. PubMed ID: 26166682
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
14. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
15. Albiglutide for the treatment of type 2 diabetes.
Muscogiuri G; Gastaldelli A
Drugs Today (Barc); 2014 Oct; 50(10):665-78. PubMed ID: 25374965
[TBL] [Abstract][Full Text] [Related]
16. Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.
Johnson KM
Curr Opin Investig Drugs; 2010 Apr; 11(4):455-63. PubMed ID: 20336594
[TBL] [Abstract][Full Text] [Related]
17. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
20. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
